KURA ONCOLOGY, INC. Payments to Acquire Marketable Securities
KURA ONCOLOGY, INC. (KURA) reported Payments to Acquire Marketable Securities of $418.46 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2024-11-07
- KURA ONCOLOGY, INC. payments to acquire marketable securities for the quarter ending 2024-09-30 was $61.73M, a 36.15% decline year-over-year.
- KURA ONCOLOGY, INC. payments to acquire marketable securities for the quarter ending 2024-06-30 was $161.67M, a 15.79% increase year-over-year.
- KURA ONCOLOGY, INC. payments to acquire marketable securities for the quarter ending 2024-03-31 was $195.06M, a 164.19% increase year-over-year.
- KURA ONCOLOGY, INC. payments to acquire marketable securities for the quarter ending 2023-12-31 was $99.69M, a 6.06% decline year-over-year.
- KURA ONCOLOGY, INC. payments to acquire marketable securities for fiscal 2023 was $409.82M, a 51.42% increase from fiscal 2022.
- KURA ONCOLOGY, INC. payments to acquire marketable securities for fiscal 2022 was $270.65M, a 39.27% decline from fiscal 2021.
- KURA ONCOLOGY, INC. payments to acquire marketable securities for fiscal 2021 was $445.66M, a 38.85% increase from fiscal 2020.
- KURA ONCOLOGY, INC. payments to acquire marketable securities for fiscal 2020 was $320.96M, a 41.04% increase from fiscal 2019.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-09-30 | $61.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $223.40M derived: sum of 2 quarters · filed 2024-11-07 | $418.46M 10-Q · filed 2024-11-07 | $518.15M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $161.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $356.74M 10-Q · filed 2024-08-08 | $456.43M derived: sum of 3 quarters · filed 2024-08-08 | $553.10M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $195.06M 10-Q · filed 2024-05-02 | $294.75M derived: sum of 2 quarters · filed 2024-05-02 | $391.42M derived: sum of 3 quarters · filed 2024-11-07 | $531.05M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $99.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $196.36M derived: sum of 2 quarters · filed 2024-11-07 | $335.99M derived: sum of 3 quarters · filed 2024-11-07 | $409.82M 10-K · filed 2024-02-27 |
| 2023-09-30 | $96.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $236.30M derived: sum of 2 quarters · filed 2024-11-07 | $310.13M 10-Q · filed 2024-11-07 | $416.26M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $139.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $213.46M 10-Q · filed 2024-08-08 | $319.59M derived: sum of 3 quarters · filed 2024-08-08 | $376.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $73.83M 10-Q · filed 2024-05-02 | $179.96M derived: sum of 2 quarters · filed 2024-05-02 | $236.91M derived: sum of 3 quarters · filed 2024-05-02 | $293.09M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $106.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $163.08M derived: sum of 2 quarters · filed 2024-02-27 | $219.25M derived: sum of 3 quarters · filed 2024-02-27 | $270.65M 10-K · filed 2024-02-27 |
| 2022-09-30 | $56.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $113.13M derived: sum of 2 quarters · filed 2023-11-02 | $164.53M 10-Q · filed 2023-11-02 | $180.87M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $56.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $107.58M 10-Q · filed 2023-08-09 | $123.92M derived: sum of 3 quarters · filed 2024-02-27 | $200.15M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $51.40M 10-Q · filed 2023-05-10 | $67.74M derived: sum of 2 quarters · filed 2024-02-27 | $143.97M derived: sum of 3 quarters · filed 2024-02-27 | $273.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $16.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $92.57M derived: sum of 2 quarters · filed 2024-02-27 | $222.50M derived: sum of 3 quarters · filed 2024-02-27 | $445.66M 10-K · filed 2024-02-27 |
| 2021-09-30 | $76.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $206.16M derived: sum of 2 quarters · filed 2022-11-03 | $429.32M 10-Q · filed 2022-11-03 | $557.34M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $129.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $353.09M 10-Q · filed 2022-08-03 | $481.11M derived: sum of 3 quarters · filed 2023-02-23 | $577.23M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $223.16M 10-Q · filed 2022-05-04 | $351.18M derived: sum of 2 quarters · filed 2023-02-23 | $447.30M derived: sum of 3 quarters · filed 2023-02-23 | $532.85M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $128.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $224.15M derived: sum of 2 quarters · filed 2023-02-23 | $309.69M derived: sum of 3 quarters · filed 2023-02-23 | $320.96M 10-K · filed 2023-02-23 |
| 2020-09-30 | $96.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $181.67M derived: sum of 2 quarters · filed 2021-11-04 | $192.94M 10-Q · filed 2021-11-04 | $223.69M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $85.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $96.82M 10-Q · filed 2021-08-05 | $127.56M derived: sum of 3 quarters · filed 2022-02-24 | $222.52M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $11.27M 10-Q · filed 2021-05-06 | $42.02M derived: sum of 2 quarters · filed 2022-02-24 | $136.97M derived: sum of 3 quarters · filed 2022-02-24 | $188.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $30.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $125.70M derived: sum of 2 quarters · filed 2022-02-24 | $176.72M derived: sum of 3 quarters · filed 2022-02-24 | $227.57M 10-K · filed 2022-02-24 |
| 2019-09-30 | $94.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $145.98M derived: sum of 2 quarters · filed 2020-11-05 | $196.82M 10-Q · filed 2020-11-05 | $230.81M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $51.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $101.87M 10-Q · filed 2020-08-06 | $135.85M derived: sum of 3 quarters · filed 2021-02-24 | $232.47M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $50.85M 10-Q · filed 2020-05-04 | $84.83M derived: sum of 2 quarters · filed 2021-02-24 | $181.44M derived: sum of 3 quarters · filed 2021-02-24 | $212.08M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $33.98M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $130.59M derived: sum of 2 quarters · filed 2021-02-24 | $161.24M derived: sum of 3 quarters · filed 2021-02-24 | $237.44M 10-K · filed 2021-02-24 |
| 2018-09-30 | $96.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $127.25M derived: sum of 2 quarters · filed 2019-11-05 | $203.46M 10-Q · filed 2019-11-05 | $224.84M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $30.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $106.85M 10-Q · filed 2019-08-01 | $128.23M derived: sum of 3 quarters · filed 2020-02-25 | $188.13M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $76.21M 10-Q · filed 2019-05-07 | $97.59M derived: sum of 2 quarters · filed 2020-02-25 | $157.48M derived: sum of 3 quarters · filed 2020-02-25 | $166.30M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $21.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $81.28M derived: sum of 2 quarters · filed 2020-02-25 | $90.09M derived: sum of 3 quarters · filed 2020-02-25 | $100.64M 10-K · filed 2020-02-25 |
| 2017-09-30 | $59.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $68.71M derived: sum of 2 quarters · filed 2018-11-05 | $79.25M 10-Q · filed 2018-11-05 | $94.47M derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | $8.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $19.36M 10-Q · filed 2018-08-06 | $34.58M derived: sum of 3 quarters · filed 2018-08-06 | $52.34M derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-03-31 | $10.54M 10-Q · filed 2018-05-08 | $25.76M derived: sum of 2 quarters · filed 2018-05-08 | $43.52M derived: sum of 3 quarters · filed 2018-05-08 | $62.97M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $15.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $32.98M derived: sum of 2 quarters · filed 2018-03-12 | $52.42M derived: sum of 3 quarters · filed 2018-03-12 | $56.43M 10-K · filed 2018-03-12 |
| 2016-09-30 | $17.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $37.20M derived: sum of 2 quarters · filed 2017-11-07 | $41.21M 10-Q · filed 2017-11-07 | $87.64M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | $19.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $23.45M 10-Q · filed 2017-08-07 | $69.88M derived: sum of 3 quarters · filed 2017-08-07 | $73.75M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-03-31 | $4.00M 10-Q · filed 2017-05-15 | $50.44M derived: sum of 2 quarters · filed 2017-05-15 | $54.30M derived: sum of 3 quarters · filed 2017-05-15 | |
| 2015-12-31 | $46.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $50.30M derived: sum of 2 quarters · filed 2017-03-14 | $76.56M 10-K · filed 2017-03-14 | |
| 2015-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $30.13M 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | $26.26M 10-Q · filed 2016-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |